Radiopharm Theranostics Limited (AU:RAD) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Radiopharm Theranostics Limited has announced a strategic partnership with Lantheus to co-develop innovative radiopharmaceuticals in Australia, focusing initially on a Phase 1 imaging trial for multiple solid tumors. Under this agreement, Lantheus will fund all clinical development costs, while Radiopharm stands to gain up to USD 2 million upon achieving specific clinical milestones. This collaboration highlights both companies’ dedication to advancing oncology treatments and addressing unmet medical needs.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Netflix (NASDAQ:NFLX) Lands Huge Win With “Squid Game 2”
- Ford (NYSE:F) Lands New Patent for “Steer-by-Wire” System
- Intel (NASDAQ:INTC) Looking Into Battlemage Followup
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
